Evidence map›Paper›PMID 39183935›Full record

ArticleChemical science2024

Fast photochromism of helicene-bridged imidazole dimers.

Katsuya Mutoh, Jiro Abe

Abstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Organic Spin-State Photoswitches.Angewandte Chemie (International ed. in English) · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katsuya MutohDepartment of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University Sagamihara Kanagawa 252-5258 Japan jiro_abe@chem.aoyama.ac.jp.ORCID https://orcid.org/0000-0002-9778-8329
Jiro AbeDepartment of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University Sagamihara Kanagawa 252-5258 Japan jiro_abe@chem.aoyama.ac.jp.ORCID https://orcid.org/0000-0002-0237-815X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unique optical and magnetic properties of organic biradicaloids on polycyclic aromatic hydrocarbons are of fundamental interest in the development of novel organic optoelectronic materials. Open-shell π-conjugated molecules with helicity have recently attracted a great deal of attention due to the magnetic-field-dependence and spin-selectivity arising from the combination of helical chirality and electron spins. However, the molecular design for helical biradicaloids is limited due to the thermal instability and high reactivity. Herein, we achieved fast photochromic reactions and reversible photo-generation of biradical species using helicene-bridged imidazole dimers. A [9]helicene-bridged imidazole dimer exhibits reversible photochromism upon UV light irradiation. The transient species produced reversibly by UV light irradiation exhibited ESR spectra with a fine structure characteristic of a triplet radical pair, indicating the reversible generation of the biradical. The half-life of the thermal recombination reaction of the biradical was estimated to be 29 ms at 298 K. Conversely, a substantial activation energy barrier was confirmed for the intramolecular recombination reaction in the [7]helicene-bridged imidazole dimer, attributed to the extended pitch length of [7]helicene. The temperature dependence of the thermal back reactions revealed that the [7]helicene and [9]helicene moieties functioned as 'soft' and 'hard' molecular bridges, respectively. These findings pave the way for future advances in the development of photoswitchable helical biradicaloids.

Identifiers

PMID39183935
PMCPMC11339945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.